The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
 
Jeremie Calais
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Chimerix; Clovis Oncology; Endocyte; Progenics
Honoraria - Progenics; Radiomedix
Consulting or Advisory Role - Blue Earth Diagnostics; Janssen
 
Jeannine Gartmann
No Relationships to Disclose
 
Wesley R Armstrong
No Relationships to Disclose
 
Pan Thin
No Relationships to Disclose
 
Kathleen Nguyen
No Relationships to Disclose
 
Vincent Lok
No Relationships to Disclose
 
Laura Gosa
No Relationships to Disclose
 
Roger Slavik
No Relationships to Disclose
 
Magnus Dahlbom
No Relationships to Disclose
 
Ken Herrmann
No Relationships to Disclose
 
Matthias Eiber
Consulting or Advisory Role - ABX Advanced biochemical compounds; Blue Earth Diagnostics
Research Funding - ABX Advanced biochemical compounds; Blue Earth Diagnostics; Siemens
Patents, Royalties, Other Intellectual Property - patent application for rhPSMA
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
Wolfgang Peter Fendler
No Relationships to Disclose
 
Johannes Czernin
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Advanced Accelerator Applications